Monopar Therapeutics (MNPR) News Today → The Worst is Yet to Come… (From Porter & Company) (Ad) Free MNPR Stock Alerts $0.61 0.00 (0.00%) (As of 05/31/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative May 24, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Announces CFO SuccessionMay 24, 2024 | markets.businessinsider.comMonopar Therapeutics: CFO Kim Tsuchimoto To Retire - Quick FactsMay 24, 2024 | globenewswire.comMonopar Announces CFO SuccessionMay 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Monopar Therapeutics on Strategic Shift and Pipeline PotentialMay 9, 2024 | investorplace.comMNPR Stock Earnings: Monopar Therapeutics Beats EPS for Q1 2024May 9, 2024 | finanznachrichten.deMonopar Therapeutics Inc.: Monopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | markets.businessinsider.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 9, 2024 | globenewswire.comMonopar Therapeutics Reports First Quarter 2024 Financial Results and Strategic Focus on its Radiopharma PipelineMay 1, 2024 | investing.comMonopar Therapeutics Inc (MNPR)April 18, 2024 | globenewswire.comMonopar Announces Radiopharma Presentation Selected for Society of Nuclear Medicine and Molecular Imaging 2024 Annual MeetingApril 16, 2024 | msn.comMonopar files patent protecting its MNPR-101 radiopharma optimization findingsApril 16, 2024 | finance.yahoo.comMonopar Announces Filing of Patent Protecting MNPR-101 Radiopharma Optimization FindingsApril 11, 2024 | markets.businessinsider.comBuy Rating on Monopar Therapeutics: Promising Trials and Financial Stability Highlight Growth PotentialApril 10, 2024 | globenewswire.comMonopar Initiates Radiopharma Phase 1 Clinical Trial for MNPR-101-Zr in Advanced Cancer PatientsMarch 28, 2024 | finance.yahoo.comMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsMarch 28, 2024 | globenewswire.comMonopar Reports Fourth Quarter and Full-Year 2023 Financial Results and Recent DevelopmentsMarch 6, 2024 | marketwatch.comMonpar Therapeutics Shares Rise 12% After Positive Preclinical Data for MNPR-101March 5, 2024 | markets.businessinsider.comMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramMarch 5, 2024 | globenewswire.comMonopar Announces Positive Preclinical Therapeutic Isotope Data for its MNPR-101 Radiopharma ProgramFebruary 27, 2024 | globenewswire.comMonopar Provides Update on MNPR-101-Zr Radiopharma Clinical TrialFebruary 24, 2024 | cnn.comMonopar Therapeutics IncFebruary 23, 2024 | markets.businessinsider.comDow Surges Over 150 Points; AerCap Posts Upbeat EarningsFebruary 22, 2024 | msn.comWhat's Going On With Cancer-Focused Monopar Therapeutics Stock Today?February 22, 2024 | msn.comMonopar stock jumps 60% amid preclinical data for MNPR-101February 22, 2024 | finance.yahoo.comMonopar Announces Promising Preclinical Data for its MNPR-101 Radiopharma Program Targeting Advanced CancersFebruary 20, 2024 | benzinga.comCrude Oil Moves Lower; Summit Therapeutics Shares PlummetFebruary 20, 2024 | marketwatch.comMonopar Therapeutics Shares Surge on Australia Antibody-Trial ClearanceFebruary 20, 2024 | msn.comWhy Is Cancer Drug Focused Monopar Therapeutics Stock Trading Higher On Tuesday?February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 10:02 AM with a stated reason of "LULD pause."February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 10:02 AM with a stated reason of "LULD pause." Trading set to resume at 10:02 AM. February 20, 2024 | finance.yahoo.comMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersFebruary 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 09:02 AM with a stated reason of "LULD pause."February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. February 20, 2024 | marketbeat.comTrading was temporarily halted for "MNPR" at 09:02 AM with a stated reason of "LULD pause." Trading set to resume at 09:02 AM. February 20, 2024 | globenewswire.comMonopar Receives Clearance to Proceed with First-in-Human Phase 1 Trial of Novel Radiopharmaceutical MNPR-101-Zr in Advanced CancersFebruary 10, 2024 | reuters.comKyverna Therapeutics IncJanuary 7, 2024 | finance.yahoo.comMonopar Therapeutics Inc. (MNPR)November 9, 2023 | finance.yahoo.comMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNovember 9, 2023 | finance.yahoo.comMonopar Therapeutics Reports Third Quarter 2023 Financial Results and Recent DevelopmentsNovember 9, 2023 | finance.yahoo.comMonopar Therapeutics Inc Reports Q3 2023 Financial Results and Progress in Clinical ProgramsNovember 3, 2023 | markets.businessinsider.comPromising Early Efficacy Results and Diverse Drug Development Portfolio Drive ‘Buy’ Rating for Monopar Therapeutics IncNovember 1, 2023 | finance.yahoo.comMonopar Presents Data Showing Tumor Reduction Benefit of Camsirubicin from Ongoing Phase 1b at the 2023 Connective Tissue Oncology Society (CTOS) Annual MeetingOctober 10, 2023 | finance.yahoo.comMonopar to Participate in the Roth MKM 2023 Healthcare Opportunities ConferenceSeptember 5, 2023 | finance.yahoo.comMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceSeptember 5, 2023 | finance.yahoo.comMonopar to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 10, 2023 | finance.yahoo.comMonopar Therapeutics Reports Second Quarter 2023 Financial Results and Recent DevelopmentsAugust 8, 2023 | finance.yahoo.comMonopar Provides Encouraging Camsirubicin Clinical Data UpdateAugust 8, 2023 | finance.yahoo.comMonopar Provides Encouraging Camsirubicin Clinical Data UpdateJuly 11, 2023 | finance.yahoo.comMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of SingaporeJuly 11, 2023 | finance.yahoo.comMonopar Announces MNPR-101 Radiopharma Collaboration Agreement with National University of Singapore Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address This military-backed stock “owns” AI market (Ad)The AI boom is just getting started. And the real wealth has still to be made… You must read this new presentation from Porter Stansberry. MNPR Media Mentions By Week MNPR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. MNPR News Sentiment▼1.210.76▲Average Medical News Sentiment MNPR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. MNPR Articles This Week▼31▲MNPR Articles Average Week Get Monopar Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MNPR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: Moleculin Biotech News Edesa Biotech News Gain Therapeutics News NextCure News Reviva Pharmaceuticals News NRx Pharmaceuticals News HCW Biologics News Immuneering News DURECT News Lexaria Bioscience News Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:MNPR) was last updated on 6/2/2024 by MarketBeat.com Staff From Our PartnersWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…InvestorPlaceTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProBiden replacement revealed?Paradigm PressShocking: One AI startup's revenue could surge 4,735%Manward PressBiden Nomination CANCELED?The Freeport SocietyNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Monopar Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
